Report #2897670

Received May 24, 2026

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: 76 yrs
State: MI
Recovered: Unknown
Vaccinated: Mar 11, 2026
Onset: Mar 11, 2026
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	NT357	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

Shingrix late second dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 76-year-old female patient who received Herpes zoster (Shingrix) (batch number NT357, expiry date 12-MAY-2028) for prophylaxis. Previously administered products included Shingrix (received first dose of Shingrix on 30-SEP-2023, ZS3D7 with expiry 08-OCT-2024). On 11-MAR-2026, the patient received the 2nd dose of Shingrix. On 11-MAR-2026, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: Shingrix late second dose). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 18-MAY-2026 Healthcare provider wanted to know how to proceed with a patient that received the second dose on 11-MAR-2026 after receiving the first one on 30-SEP-2023.